Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?
Executive Summary
Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class
You may also be interested in...
Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis
Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.
Liraglutide Cancer Signal Puts Agency In Uncharted Review Territory
Approving Novo Nordisk's Victoza (liraglutide) for type 2 diabetes would require FDA to surmount a substantial hurdle in the thyroid cancer signal seen with the GLP-1 analog
Liraglutide Cancer Signal Puts Agency In Uncharted Review Territory
Approving Novo Nordisk's Victoza (liraglutide) for type 2 diabetes would require FDA to surmount a substantial hurdle in the thyroid cancer signal seen with the GLP-1 analog